During the 1980s, a new class of drugs for the acute treatment of migraine attacks was developed, the triptans. These agents are selective 5-HT1B/1D serotonin receptor agonists, and were developed in order to address the underlying biological mechanism of the migraine attack. French guidelines in migraine are available since 2002. It is recommended to use a stratified treatment approach during the first consultation with the use of NSAID in first line acute treatment and triptan in second line. It is also recommended to use prophylactic treatment when the patient experience frequent and/or severe migraine attack with a bad quality of life and a real impairment.